No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
China Isotope & Radiation Corporation is dedicated to the development, production, and distribution of diagnostic and therapeutic radiopharmaceuticals, as well as radioactive source products for both medical and industrial applications throughout China. The company's operations are divided into five principal areas. Its Pharmaceuticals division focuses on creating and marketing imaging diagnostic and therapeutic radiopharmaceuticals, UBT kits and analyzers, and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment furnishes medical and industrial radioactive sources, along with associated technical support services. The Irradiation segment offers sterilization services for products such as medical devices, food, traditional Chinese medicine, and cosmetics, in addition to providing engineering, procurement, and construction (EPC) services for gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment handles the sale of radiation therapy equipment and its corresponding maintenance. Finally, the Independent Clinical Medical and Laboratory Services, and Other Business segment delivers independent clinical laboratory services to hospitals and other medical institutions, covering a range of conditions including hepatitis, endocrine disorders, bone metabolism issues, cardiovascular diseases, and diabetes. Founded in 1983, the company's main office is located in Beijing, China, and it operates as a subsidiary of China National Nuclear Corporation.
www.circ.com.cnNo one on the platform currently holds 1763.HK.
No tracked institution reports a position in 1763.HK as of their last filing.
No one on the platform has traded 1763.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.4% | 18.8% | 35.9% | — | — | — |
| Rev. Growth % | -7.6% | 10.4% | ||||
| Profit Margin % | 4.6% | 5.7% | 7.3% | |||
| Free Cash Flow Margin % | -0.7% | 0.3% | 1.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $8.5B | +4.5% | $1.66 | $1.66–$1.66 | — | 1 |
| 2027 | $9.3B | +10.1% | $1.79 | $1.79–$1.79 | — | 1 |
| 2028 | $10.3B | +10.0% | $2.05 | $2.05–$2.05 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $3.53 |
| +0.57% |
| $3.6B |
| — |
| 2172.HKMicroPort NeuroTech Limited | $8.05 | +0.00% | $4.7B | — |
| 2190.HKZylox-Tonbridge Medical Technology Co., Ltd. | $20.72 | +1.77% | $6.4B | — |
Source: Financial Modeling Prep · peers by sector/industry